RepliCel Life Sciences Inc. filed its Annual on May 01, 2023 for the period ending Dec 31, 2022. In this report its auditor, Mao & Ying LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0428 USD | +4.99% | -.--% | -4.89% |
04-18 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
2023 | RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-4.89% | 2.78M | |
+2.93% | 108B | |
+7.02% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- REPCF Stock
- News RepliCel Life Sciences Inc.
- RepliCel Life Sciences Inc. Auditor Raises 'Going Concern' Doubt